Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

Johnson & Johnson and Pfizer are two of the world's largest pharmaceutical companies with diversified healthcare portfolios.

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set ...

Despite treatment advances, there is currently no cure. Dr Chris Boshoff, chief development officer, Oncology and Rare Disease, at Pfizer Global Product Development, said: “Today, multiple ...

Stocks in Focus. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Jim Cramer, host of Mad Money, discussed on Monday ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing ...

Pfizer has unveiled its new research and development centre in Beijing, marking a significant step in the company's strategic expansion in China.